CGF 166

Drug Profile

CGF 166

Alternative Names: CGF166; Hearing loss gene therapy

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Developer GenVec; Novartis
  • Class Gene therapies
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hearing loss

Most Recent Events

  • 04 Apr 2017 Phase-I/II development for Hearing loss is ongoing in USA (Otic)
  • 25 Jul 2016 US FDA lifts clinical hold on phase I/II clinical trial in Hearing loss
  • 23 May 2016 Novartis reinitiates enrolment in a phase I/II trial for Hearing loss in USA (NCT02132130)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top